Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
作者信息
Bishop Michael R, Alyea Edwin P, Cairo Mitchell S, Falkenburg J H Frederik, June Carl H, Kröger Nicolaus, Little Richard F, Miller Jeffrey S, Pavletic Steven Z, Porter David, Riddell Stanley R, van Besien Koen, Wayne Alan S, Weisdorf Daniel J, Wu Roy, Giralt Sergio
出版信息
Biol Blood Marrow Transplant. 2010 May;16(5):563-4. doi: 10.1016/j.bbmt.2010.02.025. Epub 2010 Mar 2.
Abstract
摘要
相似文献
1
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.美国国立癌症研究所关于异基因造血干细胞移植后复发的生物学、预防及治疗的首次国际研讨会报告介绍
Biol Blood Marrow Transplant. 2010 May;16(5):563-4. doi: 10.1016/j.bbmt.2010.02.025. Epub 2010 Mar 2.
2
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.NCI 首次同种异体造血干细胞移植后复发的生物学、预防和治疗国际研讨会：来自同种异体 HSCT 后恶性疾病复发的生物学基础研究委员会的报告：移植物抗白血病/肿瘤反应。
Biol Blood Marrow Transplant. 2010 May;16(5):565-86. doi: 10.1016/j.bbmt.2010.02.005. Epub 2010 Feb 10.
3
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.来自国家癌症研究所第二次造血干细胞移植后复发的生物学、预防和治疗国际研讨会的会议记录：第三部分。异基因移植后复发的预防和治疗。
Biol Blood Marrow Transplant. 2014 Jan;20(1):4-13. doi: 10.1016/j.bbmt.2013.08.012. Epub 2013 Sep 7.
4
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.来自国家癌症研究所第二次关于造血干细胞移植后复发的生物学、预防和治疗的国际研讨会的会议记录：引言。
Biol Blood Marrow Transplant. 2013 Nov;19(11):1534-6. doi: 10.1016/j.bbmt.2013.08.016. Epub 2013 Sep 10.
5
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.NCI 首次国际造血细胞移植后复发的生物学、预防和治疗专题研讨会：血液恶性肿瘤异基因细胞移植后预防复发专题委员会报告。
Biol Blood Marrow Transplant. 2010 Aug;16(8):1037-69. doi: 10.1016/j.bbmt.2010.05.005. Epub 2010 May 24.
6
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.美国国立癌症研究所首届异基因造血干细胞移植后复发的生物学、预防和治疗国际研讨会：组织委员会总结和建议。
Biol Blood Marrow Transplant. 2011 Apr;17(4):443-54. doi: 10.1016/j.bbmt.2010.12.713. Epub 2011 Jan 9.
7
Relapse after allogeneic hematopoietic cell therapy.异基因造血细胞治疗后的复发。
Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S138-45. doi: 10.1016/j.bbmt.2009.10.023. Epub 2009 Oct 24.
8
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.NCI 首届异基因造血干细胞移植后复发的生物学、预防和治疗国际研讨会：来自非移植物抗宿主病相关造血系统复发的生物学考虑因素委员会的报告：科学现状。
Biol Blood Marrow Transplant. 2010 Jun;16(6):709-28. doi: 10.1016/j.bbmt.2010.03.002. Epub 2010 Mar 12.
9
Minimal residual disease following allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后微小残留病。
Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S94-100. doi: 10.1016/j.bbmt.2010.10.031. Epub 2010 Nov 1.
10
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.从美国国家癌症研究所第二次造血干细胞移植后复发的生物学、预防和治疗国际研讨会的会议记录：第一部分。移植后复发的生物学。
Biol Blood Marrow Transplant. 2013 Nov;19(11):1537-45. doi: 10.1016/j.bbmt.2013.08.010. Epub 2013 Sep 6.
引用本文的文献
1
IFN-γ and donor leukocyte infusions for relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation.干扰素-γ与供体白细胞输注用于异基因造血干细胞移植后复发的髓母细胞性恶性肿瘤
JCI Insight. 2025 Mar 25;10(9). doi: 10.1172/jci.insight.190655. eCollection 2025 May 8.
2
Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome.根据骨髓增生异常综合征患者的复发水平和供体来源，供体淋巴细胞输注对治疗反应和移植物抗宿主病的不同影响。
Ther Adv Hematol. 2021 Sep 23;12:20406207211043748. doi: 10.1177/20406207211043748. eCollection 2021.
3
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes.美国国立卫生研究院造血细胞移植迟发效应倡议：制定改善生存及长期预后的建议。
Biol Blood Marrow Transplant. 2017 Jan;23(1):6-9. doi: 10.1016/j.bbmt.2016.10.020. Epub 2016 Oct 29.
4
New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.儿科异基因造血干细胞移植的新前沿：针对儿童和青少年急性淋巴细胞白血病的新方法。
Bone Marrow Transplant. 2014 Oct;49(10):1259-65. doi: 10.1038/bmt.2014.114. Epub 2014 Jun 16.
5
Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation.儿童异基因造血细胞移植后急性白血病复发的预测因素。
Biol Blood Marrow Transplant. 2014 Jul;20(7):1033-9. doi: 10.1016/j.bbmt.2014.03.028. Epub 2014 Mar 30.
6
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.来自国家癌症研究所第二次关于造血干细胞移植后复发的生物学、预防和治疗的国际研讨会的会议记录：引言。
Biol Blood Marrow Transplant. 2013 Nov;19(11):1534-6. doi: 10.1016/j.bbmt.2013.08.016. Epub 2013 Sep 10.
7
Immunotherapy for pediatric leukemia.小儿白血病的免疫疗法。
Front Oncol. 2013 Jul 1;3:166. doi: 10.3389/fonc.2013.00166. eCollection 2013.
8
Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.异基因造血干细胞移植后的骨髓增生异常综合征：诊断与治疗挑战
Am J Hematol. 2012 Sep;87(9):916-22. doi: 10.1002/ajh.23174. Epub 2012 Apr 4.
9
Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant.移植物抗白血病（GVL）对小鼠急变期慢性髓性白血病（BC-CML）和慢性期慢性髓性白血病（CP-CML）：T 细胞杀伤的共同机制，但程序性死亡配体使 CP-CML 而非 BC-CML 具有 GVL 抗性。
J Immunol. 2011 Aug 15;187(4):1653-63. doi: 10.4049/jimmunol.1100311. Epub 2011 Jul 18.
10
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.同种异体造血细胞移植后免疫抑制治疗对复发性恶性肿瘤风险的影响。
Blood. 2011 Jul 14;118(2):456-63. doi: 10.1182/blood-2011-01-330217. Epub 2011 Jun 1.
本文引用的文献
1
Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.与采用清髓性预处理的无关供者移植相比，急性髓系白血病患者采用减低强度预处理的无关供者移植。
J Clin Oncol. 2009 Sep 20;27(27):4570-7. doi: 10.1200/JCO.2008.20.9692. Epub 2009 Aug 3.
2
Graft-versus-leukemia effects of transplantation and donor lymphocytes.移植及供体淋巴细胞的移植物抗白血病效应
Blood. 2008 Dec 1;112(12):4371-83. doi: 10.1182/blood-2008-03-077974.
3
Donor lymphocyte infusions: the long and winding road: how should it be traveled?供体淋巴细胞输注：漫长而曲折的道路：应如何前行？
Bone Marrow Transplant. 2008 Nov;42(9):569-79. doi: 10.1038/bmt.2008.259. Epub 2008 Aug 18.
4
Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.滤泡性淋巴瘤的异基因移植：与清髓性预处理相比，减低强度预处理后疾病进展风险更高。
Biol Blood Marrow Transplant. 2008 Feb;14(2):236-45. doi: 10.1016/j.bbmt.2007.11.004.
5
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning.骨髓瘤的减低强度预处理：与清髓性预处理相比，非复发死亡率较低但复发率较高。
Blood. 2007 Apr 15;109(8):3588-94. doi: 10.1182/blood-2006-07-036848. Epub 2006 Dec 7.
6
Immunobiology of allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植的免疫生物学
Annu Rev Immunol. 2007;25:139-70. doi: 10.1146/annurev.immunol.25.022106.141606.
7
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.一项关于供体淋巴细胞输注的1期试验，该输注通过CD3/CD28共刺激在体外进行扩增和激活。
Blood. 2006 Feb 15;107(4):1325-31. doi: 10.1182/blood-2005-08-3373. Epub 2005 Nov 3.
8
Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time.早期白血病异基因造血干细胞移植（HSCT）后的死亡原因：欧洲血液与骨髓移植组（EBMT）对致死性感染并发症及随日历时间变化情况的分析
Bone Marrow Transplant. 2005 Nov;36(9):757-69. doi: 10.1038/sj.bmt.1705140.
9
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.供体自然杀伤细胞同种异体反应性在不匹配造血移植中的有效性。
Science. 2002 Mar 15;295(5562):2097-100. doi: 10.1126/science.1068440.
10
Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.接受去除CD8的供体淋巴细胞输注治疗异基因祖细胞移植后复发的慢性粒细胞白血病患者的长期随访
Biol Blood Marrow Transplant. 2001;7(10):568-75. doi: 10.1016/s1083-8791(01)70017-1.
Zotero 插件